Wockhardt Ltd — Investor Presentation 2024

Feb 26, 2024

26[th] February, 2024

WOCK/SEC/SE/2023-24/072

==> picture [171 x 47] intentionally omitted <==

BSE Limited National Stock Exchange of India Limited Corporate Relations Department Listing Department P J Towers, Exchange Plaza Dalal Street Bandra Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol – WOCKPHARMA

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith a copy of the Investor Presentation for your records.

The said Investor Presentation has also been uploaded on the Company’s website and can be accessed through the following link:

• https://www.wockhardt.com/investors/analyst investors/presentation/

You are requested to kindly take it on record.

Thanking you,

Yours Sincerely,

Rashmi Digitally signed by Rashmi Dinesh Dinesh Mamtura Date: 2024.02.26 Mamtura 12:14:03 +05'30'

Rashmi Mamtura

Company Secretary

Encl.: A/a.

==> picture [106 x 46] intentionally omitted <==

==> picture [480 x 31] intentionally omitted <==

==> picture [331 x 163] intentionally omitted <==

Investor presentation

2024

==> picture [186 x 105] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Disclaimer

This presentation and the accompanying slides (the “ Presentation ") contain selected information about the activities of Wockhardt Limited (" Company ") and its subsidiaries (together, the “ Group ") as at the date of this presentation. It does not purport to present a comprehensive overview of the Group or contain all the information necessary to evaluate an investment in the Company.

The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or, the recommendation or solicitation of an offer or invitation to purchase any securities of the Company in India, the United States or any other jurisdiction. This presentation should not, nor should anything contained in it, form the basis of, or be relied upon in any connection with any contract or commitment whatsoever.

This presentation is not intended to be a “prospectus” or “ or “draft offer document” or “offer document” or “final offer document” or “offer letter” or “offering memorandum”(as defined or referred to, as the case may be, under the Companies Act, 2013 and the rules notified thereunder or any other applicable law, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended). It is clarified that this Presentation is not intended to be a document or advertisement offering for subscription or sale of any securities or inviting offers or invitations to offer or solicitation to offer from the public (including any section thereof) or any class of investors. This document has not been and will not be reviewed or approved by a regulatory authority in India or elsewhere or by any stock exchange in India or elsewhere. The distribution of this presentation in certain jurisdictions may be restricted by law, and the recipients into whose possession the presentation come should inform themselves about and observe such restrictions. Any decision to purchase securities in the context of an offering of securities (if any) should be made solely on the basis of information contained in the offering documentation published in relation to such offering. You will be solely responsible for your own assessment of the market and the market position of the Group, and you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

This Presentation and the information contained herein, is strictly confidential and is intended only for the exclusive use of the recipients thereof, subject to the provisions stated herein, and may not be disclosed, reproduced, published, transmitted, summarized, distributed or furnished, in or whole or in part, or passed on directly or indirectly to any other person or persons whether within or outside your organization or firm, or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. Any printed form of this Presentation must be returned to us immediately at the conclusion of this Presentation. This Presentation is being communicated to selected persons who have professional experience in matters relating to investments for information purposes only and does not constitute a recommendation regarding any securities of the Group. Other persons should not rely or act upon this Presentation or any of its contents.

The Group may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such revision or changes. This presentation may contain forward looking statements that involve risks and uncertainties. Forward looking statements are based on certain beliefs, plans and expectations of the Group about the future. Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy, future outlook and growth prospects, and future developments in businesses and/or competitive and regulatory environment No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that any objectives specified herein will be achieved. Actual future performance, outcomes and results may differ materially from those expressed in forward looking

statements as a result of a number of risks, uncertainties and assumptions. Although the Group believes that such forward looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Representative examples of factors that could affect the accuracy of forward looking statements include (without limitation) the condition of and changes in India’s political and economic status, government policies, applicable laws, the industries relevant to the Group in India, and international and domestic events having a bearing on the Group’s business, and such other factors beyond the Group’s control. You are cautioned not to place undue reliance on these forward looking statements, which are based on current views of the Group’s management on future events.

If the Company should at any time make an offering of securities, any decision to invest in any such offer to subscribe for or acquire securities of the Company must be based wholly on the information contained in the offer document or offering circular, placement document, and/or any international offering memorandum (including the risk factors mentioned therein) issued or to be issued by the Company in connection with any such offer and not on the contents herein. Information contained in this presentation is qualified in its entirety by reference to an offering document for any potential transaction if it proceeds. Any potential transaction could be made available to the recipient of this document in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to the recipient, herein or otherwise.

No representation or warranty express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein and, accordingly, none of the Group, its directors, officers or employees or its affiliates, its advisors or representatives, or any such person's officers or employees accepts any liability (in negligence or otherwise) whatsoever arising directly or indirectly from the use of this presentation.

The contents of this presentation have not been independently verified and this presentation has been prepared by the Group, solely for informational purposes Neither the delivery of this presentation nor any further discussions with any of the recipients shall, under any circumstance, create any implication that there has been no change in the affairs of the Group. This presentation is a summary only and it is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the financial position or prospects of the Group.

Certain data contained in this presentation was obtained from various external data sources, and none of the Group, its advisers or representatives has verified this data with independent sources Accordingly, the Group, its advisers and representatives make no representation as to the fairness, accuracy, correctness, authenticity or completeness of that data, and this data involves risks and uncertainties and is subject to change based on various factors. The information contained in this presentation is not to be taken as any recommendation made by the Group or any other person to enter into any agreement with regard to any investment. You will be solely responsible for your own assessment of the market and the market position of the Group, and you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

By participating in this Presentation, attendees agree to be bound by the foregoing limitations Any failure to comply with these restrictions may constitute a violation of applicable securities law

==> picture [79 x 24] intentionally omitted <==

2

Snapshot of Wockhardt

Net sales Revenues INR 2,129 Cr. (9M FY24) EBITDA INR 173 Cr. (9M FY24) Net Debt: Equity Ratio 0.27x (as on September 30, 2023) International Business 78% (9M FY24) Biotechnology Pharma Generics Vaccines (focus on Diabetes)*

12 manufacturing facilities across world ~~2~~ R&D centres one each in India, UK ~ 315 scientists with 55 PhD’s; Drug Discovery team ~ 125 associates 3,262 patents filed; 837 patents granted New Chemical Entity Vaccines (focus on novel Antibiotics)

==> picture [79 x 24] intentionally omitted <==

• Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances

3

Global footprint

Global operations

Capability across different segments

==> picture [52 x 50] intentionally omitted <==

► Branded ► Antibiotics Drug Discovery ► OTC ► Biotechnology ► Hospitals ► Pharma Generics

• Solids ► Liquids

• ► Injectables ► Nasal sprays ► Biotechnology ► Complex technologies

• Direct operations Through Partners

==> picture [882 x 14] intentionally omitted <==

USA

United Kingdom Emerging Markets

India

• United Kingdom Emerging Markets India Ireland USA

• ► Retail & Hospital ► Presence in ► Pain, Diabetes, ► Branded Generic & ► Restructuring - segments facility shutdown Southeast Asia, Nephrology, CNS OTC

• ► Vaccine CMO ► Shift to third party East Asia, Africa, portfolio ► Retail pharmacies, manufacturing

• the CIS region and ► >750** field force wholesalers &

• Latin America ► Defocusing hospitals. Pharma R&D

• countries

• 36% 21% 22% 6% 6%

==> picture [79 x 24] intentionally omitted <==

% sales revenue contribution for 9M FY23 -24

*9M FY 23-24 (Others: 9%)

4

**as on 31[st] December 2023

Financial Highlights

Net Sales Revenues INR Cr.

EBITDA INR Cr.

==> picture [868 x 392] intentionally omitted <==

----- Start of picture text -----

307
3,239
328
489
2,840
2,693 7% growth
130 80% growth
26
2,129
1,983
5
173
24
5
143
19
2,710 2,750 2,667 71 96
2,124 98 17 168
1,959
124
79
-27 -21
FY21 FY22 FY23 9M FY23 9M FY24
FY21 FY22 FY23 9M FY23 9M FY24
FY Figures Excl. Vaccine FY Figures for Vaccine 9M Figures Excl. Vaccine 9M Figures Vaccine
----- End of picture text -----

==> picture [79 x 24] intentionally omitted <==

5

Reduction in External Term Loans

Reduction in external term loan* (INR Cr.)

==> picture [851 x 337] intentionally omitted <==

----- Start of picture text -----

2,054
1,262
825
555
438
Mar-20 Mar-21 Mar-22 Mar-23 Sep-23
----- End of picture text -----

==> picture [79 x 24] intentionally omitted <==

*Excluding promoter debt & preference capital

6

Net Debt : Equity @ 0.27*

Total Borrowings* Reduction by > INR 600 Cr.

Total Equity INR Cr.

Total Borrowings* INR Cr.

==> picture [856 x 125] intentionally omitted <==

----- Start of picture text -----

1,568
4,202
3,759 3,662 3,432 882 975 933
FY21 FY22 FY23 6M FY24 FY21 FY22 FY23 6M FY24
----- End of picture text -----

Cash & cash equivalents and other Bank balances INR Cr.

**Net Debt-Equity Ratio ***

==> picture [856 x 125] intentionally omitted <==

----- Start of picture text -----

406 0.42
292 0.27 0.27
0.21
124 84
FY21 FY22 FY23 6M FY24 FY21 FY22 FY23 6M FY24
----- End of picture text -----

==> picture [79 x 24] intentionally omitted <==

• Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances

7

Additional Short-term and Mid-term growth drivers

3 years growth drivers

Diabetes Biosimilars for India + 1 Emerging markets – Human Insulin & Glargine

Novel drug discovery - WCK 5222, 2 Nafithromycin, Emrok

3

Vaccines

1

2

5 years growth drivers

Novel drug discovery – WCK 5222, Nafithromycin, WCK 6777

Diabetes Biosimilars for India + Emerging markets – New Insulin Analogs and GLP1 Agonists

==> picture [79 x 24] intentionally omitted <==

8

New Chemical Entity (Antibiotics)

9

Anti-microbial resistance (AMR) could cause 10 million deaths by 2050

‘ Tackling Drug-Resistant infections globally’ chaired by JIM O’NEILL- Former Minister, UK Govt. & Former Chairman Goldman Sachs’

A failure to address the problem of antibiotic resistance could result in

10 Million deaths globally by 2050, costing £ 66 trillion

Deaths attributable to antimicrobial resistance every year compared to other major causes of death

AMR in 2050 10,000,000 Tetanus Cholera Measles AMR 60,000 100,000-120,000 130,000 700,000 Road traffic Diarrheal Diabetes Cancer accidents disease 1,500,000 1,400,000 1,200,000 1,400,000

http://amr-review.org/

==> picture [112 x 46] intentionally omitted <==

==> picture [79 x 24] intentionally omitted <==

10

Wockhardt’s Novel Antibiotics

~25 Focused commitment to Novel Antibiotics research leading to end-to-end Discovery & Development capabilities years

==> picture [642 x 42] intentionally omitted <==

6

Programs granted QIDP* status by US FDA denoting unmet needs; faster trials, quicker approvals by US FDA

• Qualified Infectious Disease Product (QIDP) status granted by US FDA eligible for fast track development process and priority review. QIDP status also grants five

year extension to the market exclusivity in the United States

==> picture [79 x 24] intentionally omitted <==

11

Novel Antibiotics pipeline encompassing all the Resistant Organisms

		Gram Negative Portfolio				Gram Positive Portfolio
		WCK 5222		WCK 4282	WCK 6777	Emrok / Emrok O	Nafithromycin
Status		GlobalPhase III ongoing	Meropenem resistant pathogen study (India)	Phase III ready	Phase I In collaboration with NIH (US)	Launched in India; Filed in Emerging Markets	Phase IIIcompletion in India
Potential Indication		cUTI, HABP / VABP (Global) + Carbapenem Resistant infections (India)		cUTI HABP / VABP	cUTI	ABSSSI	CABP / RTI
Target Market		Global		Global	Global	Emerging Market	Emerging Market
Positioning		Destination therapy for difficult-to-treat Gram-ve Klebsiella, Acinetobacter and Pseudomonas		Empiric-use; Carbapenem- sparing Gram-ve	Out-patient therapy for MDR Gram -ve	MDR Gram+ve Anti-MRSA	Macrolide-resistant Respiratory Pathogens, Quinolone-Sparing

==> picture [79 x 24] intentionally omitted <==

HABP: Hospital Acquired Bacterial Pneumonia; VABP: Ventilator Acquired Bacterial Pneumonia cUTI : Complicated urinary tract infections; CABP: Community-acquired bacterial pneumonia ; RTI: Respiratory Tract Infection; ABSSSI: Acute bacterial skin and skin structure infections; MDR: Multidrug resistance ; Gram –ve: Gram Negative ; Gram +ve: Gram Positive

12

WCK 5222 Development Status (Brand name: Zaynich[TM] *)

WCK 5222 (Cephalosporin + β-lactam enhancer) – Destination therapy for XDR Gram Negative Acinetobacter & Pseudomonas

Pre-clinical

Phase I Phase II[1]

Completed

Global Phase III Regulatory (on-going) filings

Global Launch

• Phase I studies completed

Unmet Need

• Pulmonary PK, renal impairment and cardiovascular safety studies completed

• Phase III clinical study based on US FDA accepted development path

• Global Phase III cUTI study ongoing: >50% patient recruitment completed

• Meropenem-resistant clinical study set for first patient recruitment for early launch in India

• Patents secured in key global markets; strong IP protection

• Carbapenem resistant Pseudomonas and Acinetobacter (20-95%) infections are desperately treated with efficacy and safetycompromised colistin/polymyxin/tigecycline.

• WCK 5222 would provide a safer and consistently efficacious therapy for such life-threatening infections.

Compassionate Use

100% clinical and microbiological success thus far in 15 patients with extremely difficult to treat infections, where all the available therapies failed

==> picture [79 x 24] intentionally omitted <==

1. Phase II waiver

13

*- Trademark filed in India

WCK 5222: Compassionate use results in 15 patients (incl. 2 paediatric) (1/2)

#.	Patients with Life threatening infections	Failed treatment	Pathogen and Drug Resistance	Pathogen and Drug Resistance	DRUG RESISTANCE	DRUG RESISTANCE	DRUG RESISTANCE	DRUG RESISTANCE	WCK 5222	WCK 5222	WCK 5222	WCK 5222
					Drug 1	Drug 2	Drug 3	Drug 4	Treat- ment Duration	Efficacy	Safety	Outcomes
1	Complicated intra-abdominal infection induced-sepsis	Polymyxin-B (2 weeks)	XDR	Pseudomonas aeruginosa	R	R	R	R	10 days	✓	✓	•Complete resolution of infection •Patient’s Clinical condition improved ~~•~~Well tolerated ~~•~~WCK 5222 was well tolerated even at adult doses in paediatric patients
2	Febrile neutropenia, Thalassemia major, failed bone marrow transplant, bloodstream infection	PIP/TAZ, Meropenem, CAZ/AVI & Aztreonam	XDR	Escherichia coli	R	R	R	R	20 days	✓	✓
3	Acute T cell lymphoblastic leukaemia, pneumonia, bloodstream infection	Polymyxin-B & Meropenem therapy	XDR	Pseudomonas aeruginosa	R	R	R	R	32 days	✓	✓
4	Lung infection leading to empyema, lung part excision with chronicpulmonaryTB	CAZ/AVI & Aztreonam (3 weeks) as well as Colistin(1 week)	Pan- drug resistant	Pseudomonas aeruginosa	R	R	R	R	22 days	✓	✓
5	Bilateral sequential lung transplant, osteomyelitis,	Multiple rounds of Tigecycline, CAZ/AVI, Meropenem	MDR	Serratia marcescens	R	R	S	R	22 days	✓	✓
6	Osteomyelitis + maxillary sinusitis & pneumonia	Colistin, Fosfomycin (6 weeks), Meropenem (2 weeks)	MDR	Pseudomonas Resistant to>>	R	R	R	R	70 days	✓	✓
7	Osteomyelitis (bone infection of chest wall)	Colistin therapy	MDR	Pseudomonas Resistant to>>	R	R	R	R	49 days	✓	✓
8	Bronchopleural fistula, Ventilated Pneumonia	Polymyxin-B and ceftazidime/avibactam therapy	MDR	Pseudomonas & Acinetobacter	R	R	R	R	10 days	✓	✓

100% clinical and microbiological success

==> picture [79 x 24] intentionally omitted <==

14

Drug 1: Carbapenems ; Drug 2. Ceftazidime/ Avibactam (CAZ/AVI) Drug 3.Imipenem/ Relebactam; Drug 4.Ceftolozane/ Tazobactam

R: Resistant; S: Susceptible

WCK 5222: Compassionate use results in 15 patients (incl. 2 paediatric) (2/2)

#	Patients with Life threatening infections	Failed treatment	Pathogen and Drug Resistance	Pathogen and Drug Resistance	DRUG RESISTANCE	DRUG RESISTANCE	DRUG RESISTANCE	DRUG RESISTANCE	WCK 5222	WCK 5222	WCK 5222	WCK 5222
					Drug 1	Drug 2	Drug 3	Drug 4	Treat- ment Duration	Efficacy	Safety	Outcomes
9	Liver Transplant, HTN, Hypothroidism, Hospital- acquired Pneumonia on Ventilation	Colistin and Doripenem therapy	MDR	Pseudomonas Resistant	R	R	R	R	12 Days	✓	✓	•Complete resolution of infection •Patient’s Clinical condition improved •Well tolerated •WCK 5222 was well tolerated even at adult doses in paediatric patients .
10	Endovascular Infection Post Arterialgraft	Multiple rounds of CAZ/AVI+Aztreonam	MDR	Pseudomonas Resistant	R	R	R	R	14 Days	✓	✓
11	Urosepsis & septic shock, on ventilation & inotropic support	Colistin, Meropenem, PIP/TAZ	MDR	Pseudomonas aeruginosa	R	R	R	R	30 Days	✓	✓
12	Pancytopenia, abscess in liver , consistent fever spikes	Colistin, CAZ/AVI+Aztreonam, Meropenem	MDR	Klebsiella pneumoniae	Isolate not available for WCK 5222 susceptibility testing. Patient treated with WCK 5222 empirically at the discretion of clinician				30 Days	✓	✓
13	Severe septic shock, fever spikes, lung infection and required inotropic support	Fosfomycin, Colistin and Levofloxacin	Pan-drug resistant	Pseudomonas aeruginosa	R	R	R	R	5 Days	✓	✓
14	Bone and Joint Infection: Left malignant otitis externa w/ lateral skull base osteomyelitis	No other antibiotics tried based on past experience of treating physician	MDR	Pseudomonas aeruginosa	R	R	R	R	42 Days	✓	✓
15	Complicated Intra Abdominal Infection with Spleen abscess (Recurrent abscess/sepsis)	with Fosfomycin	MDR	Pseudomonas aeruginosa	R	R	R	R	28 Days	✓	✓

100% clinical and microbiological success

==> picture [79 x 24] intentionally omitted <==

15

Drug 1: Carbapenems ; Drug 2. Ceftazidime/ Avibactam (CAZ/AVI) Drug 3.Imipenem/ Relebactam; Drug 4.Ceftolozane/ Tazobactam

R: Resistant; S: Susceptible

Pathogens inflicting infections and associated indications while treating 15 patients with WCK 5222 in compassionate setting

Complete clinical as well as microbiological cure attained in all patients

==> picture [368 x 296] intentionally omitted <==

----- Start of picture text -----

Indication wise split for patients treated
under compassionate use
Bone & Joint 22-70 days
Infection
Complicated cUTI with
4
Intra- Pseudomon
Abdominal as Sepsis
Infection 1
2 30 days
28-30 days 15
patients
Blood
3 5
Stream
Pneumonia
infection
(HABP, VABP,
5-20 days
empyema)*
10-32 days
Treatment duration
----- End of picture text -----**

Pathogen	15 Patients treated	Treatment duration
Pseudomonas aeruginosa 11a 5 to 70 days
Acinetobacter baumannii + Pseudomonas aeruginosa 1b 10 days
Escherichia coli 1c 20 days
Serratia marcescens 1d 22 days
Klebsiella pneumoniae 1e 30 days

• a. 9/11 patients had Colistin / Polymyxin failure; 3/11 patients had CAZ/AVI & Aztreonam failure; 1/11 patients had Fosfomycin IV failure

• b. Patient had Polymyxin & CAZ/AVI failure

• c. Patient had CAZ/AVI + Aztreonam failure

• d. Patient had CAZ/AVI & Tigecycline failure

• e. Patient had CAZ/AVI + Aztreonam & Colistin failure

• 1/5 patients also had cIAI, 1/5 patients also had cSSSTI & BSI

• ** 1/4 patients also had pneumonia

Polymyxin-B / Colistin therapy had already failed in 10 out of these 15 patients; WCK 5222 dose adjustment was required in only 4 out of these 10 patients

==> picture [79 x 24] intentionally omitted <==

16

Strictly confidential. Not for further circulation

WCK 5222 differentiation

Activity against resistant infection		Best comparable Pipeline	Best comparable Pipeline	Best comparable Pipeline	Drugs					Best available Approved Drugs	Best available Approved Drugs	Best available Approved Drugs
Organism/ Resistance Mech.		WCK 52221	Product 1	Product 2				Product 3	Product 4	Product 5	Product 6	Product 7	Product 8	Product 9
K. pneumoniae(ESβL)
K. pneumoniae(KPC)
K. pneumoniae(MβL)
E. coli(PBP3 insert+ESBL/Class C)
E. coli(MβL± PBP3 Insert)
Enterobacter (AmpC)
Proteus (ESβL, Class C)
P. aeruginosa(AmpC + oprD +Efflux)
P. aeruginosa(Oxa, oprD + Efflux)
P. aeruginosa(MβL)
A. baumannii(CHDL, OXA)
_S. maltophilia_MDR/XDR
		Most Isolates Susceptible				Variable Susceptibility				Most Isolates Resistant

1. WCK 5222: Wockhardt’s combination of Cefepime (Cephalosporin) with Zidebactam (β-lactam enhancer); Product 1.Cefepime/taniborbactam ; Product 2.Aztreonam/avibactam ; Product 3. Cefiderocol ; Product 4.Imipenem/relebactam ;Product 5.Meropenem/vaborbactam ; Product 6.Plazomicin ; Product 7.Ceftazidime/avibactam ; Product 8.Sulbactam/durlobactam ;Product 9.Imipenem or meropenem

==> picture [79 x 24] intentionally omitted <==

17

Top 6 Super bugs inflicting global mortality in 2019 - more than 3.5 Millions deaths

Number of deaths associated with Anti-Microbial Resistance*

==> picture [812 x 240] intentionally omitted <==

----- Start of picture text -----

829,000
748,000
642,000
596,000
423,000
334,000
----- End of picture text -----

Acinetobacter Escherichia Coli Klebsiella Pseudomonas Staphylococcus Pneumococcus

WCK 5222 is designed to address all the major Super Bugs including Pseudomonas, Klebsiella, E. coli and Acinetobacter

==> picture [79 x 24] intentionally omitted <==

* Lancet. 2022 Feb 12;399(10325):629-655

18

Nafithromycin (Brandname: Miqnaf[TM] *): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) and Upper Respiratory tract infections(RTI)

Increasing resistance and incomplete coverage for current treatment options:

• 1 • Azithromycin resistance in S. Pneumonia of ~65% in India**

• Lack of atypical pathogen coverage by Amoxicillin/Clavulanic acid

==> picture [156 x 296] intentionally omitted <==

----- Start of picture text -----

2
5
----- End of picture text -----

Nafithromycin has broad spectrum (covers entire range of gram +ve, gram -ve & atypicals) enabling 2 monotherapy; effective against Azithromycin resistant strains / multi-drug resistance bacteria with 100% coverage based on high lung concentrations

Successfully completed phase III study with 96.77 % of cure rate in CABP and other respiratory 3 infections, with safety profile commensurate with community usage

• 4 Lung penetration profile - Human lung exposure 8 times higher than Azithromycin Ultra short duration therapy (3 day) with Once Daily dosing treatment regimen for improved patient

• 5 compliance

==> picture [54 x 53] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

Phase I and Phase II conducted by reputed global CRO’s in US & EU. Phase III completed in India and commercialization expected in short term

• *- Trademark filed in India

• *-AMR Surveillance Network, Indian Council of Medical Research, 2022. Susceptibility and resistance to Azithromycin is determined by testing Erythromycin as per CLSI

==> picture [79 x 24] intentionally omitted <==

19

EMROK & EMROK O: Multi-spectrum anti-MRSA Drug

Emrok / Emrok O[®] : Launched in India and filed in select Emerging markets

==> picture [106 x 93] intentionally omitted <==

New Age Antibiotic : Benzoquinolizine sub-class

==> picture [186 x 75] intentionally omitted <==

==> picture [106 x 93] intentionally omitted <==

Multi-spectrum activity: Safe Oral and IV antibiotic with coverage of MDR Gram Positive pathogens including MRSA, Gram Negative, Anaerobic & Atypicals

==> picture [106 x 93] intentionally omitted <==

EMROK & EMROK O - Only rapidly bactericidal agent available for MRSA infections with excellent penetration in Biofilms associated with Bone and Joint infections, Prosthetic Joint infections and Catheter-associated infections

==> picture [79 x 24] intentionally omitted <==

20

==> picture [376 x 112] intentionally omitted <==

Biotechnology

==> picture [224 x 34] intentionally omitted <==

==> picture [189 x 93] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

Strategic pillars of Diabetes Biosimilars

Focus on Diabetes Injectable portfolio

==> picture [61 x 61] intentionally omitted <==

Human Insulin, Insulin Glargine commercialized

==> picture [51 x 52] intentionally omitted <==

Robust Pipeline of Insulin Analogs and GLP1 Agonists under development

Vertically integrated

==> picture [39 x 38] intentionally omitted <==

Research and Development Yeast, mammalian and bacterial platform

==> picture [83 x 39] intentionally omitted <==

Drug substance manufacturing

4 facilities

==> picture [83 x 39] intentionally omitted <==

Drug product manufacturing

2 facilities

==> picture [38 x 39] intentionally omitted <==

Patented delivery device Disposable Pen, Reusable Pen

==> picture [44 x 44] intentionally omitted <==

Business Organization

Direct presence in 10 Emerging markets (incl. India)

==> picture [79 x 24] intentionally omitted <==

22

Competitive advantage by providing end-to-end solutions in Diabetes Biosimilars

Integrated capabilities R&D Manufacturing Regulatory Devices Focus on Insulin Pilot to large scale Registrations in 40+ Customised precision analogues, GLP1 capabilities for API & countries patented delivery agonists formulations devices Pipeline of Insulin Analogs including Insulin Aspart & Lispro Enhanced competitive posture to help penetrate markets Patented delivery Vials Cartridges devices (pen)

==> picture [79 x 24] intentionally omitted <==

23

Development status of Insulin analogues and GLP-1 agonist

	Aspart R	Aspart 30/70	Lispro R	Lispro 25/75	Liraglutide
Process development	✓	✓	✓	✓	✓
Process Scale Up	✓	✓	✓*	✓*	Ongoing
Drug substance validation batches	✓	✓	✓*	✓*	Planned
Drug product validation batches	✓	Planned	Planned	Planned
PK/PD study	✓
Analytical similarity	Ongoing

E.Coli host cell as platform technology for all above products

✓ Completed

• To be further scaled up

==> picture [79 x 24] intentionally omitted <==

24

Diabetes Biosimilars for Emerging markets - Competitive scenario

==> picture [869 x 419] intentionally omitted <==

----- Start of picture text -----

6-7 Barriers to entry -
1 Limited competition development time,
players dedicated manufacturing
Under registration in 7
2 Registered in emerging markets > 40 markets
countries
API +
3 Manufacturing infrastructure ready Low cost manufacturing
Formulation
Competitive
scenario
Development
4 Integrated end to end capabilities Own patented device
to marketing
> US$ 1.5 Potential for deeper
5 Focus on Human Insulin & Insulin Glargine
Billion market market penetration
~ US$ 1.1
6 Pipeline: Aspart R & Aspart Mix PK/PD development stage
Billion market
----- End of picture text -----

==> picture [79 x 24] intentionally omitted <==

25

Vaccine: Supply & Collaboration agreement with Serum at UK Facility

• Profit sharing of 51:49 with Serum Life Sciences Limited in favor of Wockhardt

• 15 years arrangement

• Reserved capacity of 150 million doses per annum

==> picture [79 x 24] intentionally omitted <==

26

Abbreviation

ABSSSI: Acute bacterial skin and skin structure infections; AmpC : AmpC beta-lactamases AMR: Antimicrobial resistance API: Active Pharmaceutical Ingredient CIS: Commonwealth of Independent States CABP: Community-acquired bacterial pneumonia CHDL: Carbapenem-hydrolyzing class D β-lactamases CLSI: Clinical & Laboratory Standards Institute CMO : Contract Manufacturing Organization CNS: Central Nervous System CRO : Clinical research Organisation cUTI : Complicated urinary tract infections EBITDA: Earnings before Interest, Tax, Depreciation and Amortization ESBL : Extended Spectrum Beta-Lactamase GLP1: Glucagon-like peptide 1 GMP: Good Manufacturing Practice HABP: Hospital Acquired Bacterial Pneumonia KPC : Klebsiella pneumoniae carbapenemase

MBL : Metallo-β-lactamases MDR: Multidrug resistance MENA: Middle East and North Africa MRSA : Methicillin-resistant Staphylococcus aureus NIH (US): National Institutes of Health (NIH), OD: Once a day OTC : Over the counter PBP3: Penicillin-binding protein 3 PK/PD study : Pharmacokinetic-Pharmacodynamic R&D: Research and Development RTI: Respiratory Tract Infection; USFDA : United States Food and Drug Administration. VABP: Ventilator Acquired Hospital Pneumonia WCK 4282: Cefepime/Tazobactam WCK 5222: Cefepime/Zidebactam WCK 6777: Ertapenem/Zidebactam XDR : Extensively Drug Resistant

==> picture [79 x 24] intentionally omitted <==

27

Thank You

28